Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046136 · ClinicalTrials.gov registry record · Phase 2
Mucinex Exploratory Cold Study
A Phase 2 study, sponsored by Reckitt Benckiser.
- Completed
- Registry status
- Phase 2
- Development phase
- 378
- Enrollment target
NCT01046136 is a Phase 2 study that has completed, run by Reckitt Benckiser. The registered enrollment target is 378 participants.
The verdict
NCT01046136, a Phase 2 study, has completed, sponsored by Reckitt Benckiser.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 378 participants
- Enrollment target
Study Summary
This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
Interventions
- DRUG placebo
- DRUG guaifenesin (Mucinex)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01046136
The ClinicalTrials.gov registry entry for NCT01046136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01046136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01046136 about?
NCT01046136 is a clinical study titled "Mucinex Exploratory Cold Study". This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
What is the current status of trial NCT01046136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 378 participants. The study started on 2009-12.
What interventions are being tested in trial NCT01046136?
The interventions under investigation include: placebo (DRUG), guaifenesin (Mucinex) (DRUG).
Who is sponsoring clinical trial NCT01046136?
This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.